Investors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with shares marking time in premarket trading despite a reorganisation that signals the US drugmaker is bracing for the biggest revenue hit in its recent history.

The Wall Street Journal reported on Monday that Merck plans to separate its human-health operations into two distinct divisions. One will house its cancer treatments, anchored by Keytruda, and the other will carry its non-cancer products.

The logic is straightforward, even if the timing is uncomfortable. Keytruda, approved for multiple cancer types, generated more than $30 billion in sales in 2025, making it one of the best-selling drugs in the world.

That extraordinary success has also made Merck acutely vulnerable: certain patent protections on Keytruda are set to expire in 2028, opening the door to cheaper biosimilar competition that could erode revenues sharply within just a few years.

By ring-fencing the cancer business, Merck can give each division a cleaner identity and, potentially, a more focused management structure for navigating very different competitive environments.

The cancer unit will need to defend and extend Keytruda's franchise while developing successors. The non-cancer unit can grow without being overshadowed by a single product.

The move follows a period of active deal-making as Merck has sought to fill its pipeline and build new growth drivers ahead of the patent cliff. The company did not immediately respond to requests for comment.

The muted share price reaction reflects where investors are: the restructuring addresses a known problem without yet solving it. What moves the stock from here will be what goes into those pipelines, not how the business is carved up on an org chart.